View Older Stories View More Recent Stories

Nov 16, 2015 06:59AM Data from ALLY-3+ Trial Investigating Daklinza (daclatasvir) in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C Genotype 3 Patients with Advanced Fibrosis or Cirrhosis Presented at AA
Nov 12, 2015 06:59AM Bristol-Myers Squibb to Present New Data for Opdivo (nivolumab) in Advanced Melanoma, as Monotherapy and in Combination with Yervoy (ipilimumab), at the Society for Melanoma Research 2015 Internationa
Nov 11, 2015 11:00AM Bristol-Myers Squibb Foundation Awards Five Grants Totaling More than $2.77M to Programs Supporting Post-9/11 Military Veterans, their Families and Caregivers
Nov 6, 2015 04:15PM Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the American Heart Association (AHA) Scientific Sessions 2015
Nov 5, 2015 06:59AM European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) in Previously Treated Advanced Renal Cell Carcinoma
Nov 5, 2015 06:59AM Bristol-Myers Squibb to Present Data from 24 Abstracts in Immunoscience at the American College of Rheumatology (ACR) 2015 Congress
Nov 3, 2015 10:19AM Bristol-Myers Squibb and the Johns Hopkins Kimmel Cancer Center Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program
Nov 3, 2015 10:00AM Bristol-Myers Squibb to Present at Credit Suisse 2015 Health Care Conference
Nov 2, 2015 06:59AM Bristol-Myers Squibb to Acquire Cardioxyl Pharmaceuticals, Inc.
Oct 28, 2015 07:35PM Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for Yervoy (ipilimumab) as Adjuvant Treatment for Fully Resected Stage III Melanoma
Oct 28, 2015 08:36AM Bristol-Myers Squibb’s Opdivo (nivolumab) Recipient of Prix Galien USA 2015 Award for Best Biotechnology Product
Oct 27, 2015 05:36PM Market Wrap: Suprise Dip in Confidence for Oct.; Apple Gains on iPhone Sales; Walgreens Boots Moves to Acquire Peer
Oct 27, 2015 06:59AM Bristol-Myers Squibb Reports Third Quarter Financial Results
Oct 26, 2015 02:16PM Trading Radar for 10/26: Apple (AAPL), Twitter (TWTR), Alibaba (BABA), Comcast (CMCSA), Pfizer (PFE) Report
Oct 23, 2015 09:30AM Complete Phase 2a Study of HIV-1 Investigational Maturation Inhibitor Demonstrates Positive Results for Therapy Designed to Attack Virus Differently Than Existing Treatments
Oct 21, 2015 07:09AM Bristol-Myers Squibb to Present Data from Multiple Studies of Difficult-to-Treat Chronic Hepatitis C Patients at AASLD
Oct 15, 2015 07:01PM NICE Recommends Daklinza (daclatasvir) for Treatment of Certain Patients with Chronic Hepatitis C Genotypes 1, 3 and 4
Oct 15, 2015 02:12PM Bristol-Myers Squibb Appoints Paul Biondi Senior Vice President, Head of Business Development
Oct 15, 2015 04:00AM Bristol-Myers Squibb Enters into Exclusive Worldwide License and Collaboration Agreement with Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
Oct 15, 2015 04:00AM Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
Oct 15, 2015 04:00AM Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
Oct 14, 2015 09:05AM Market’s Only Cancer Immunotherapy ETF Launches
Oct 13, 2015 06:59AM Bristol-Myers Squibb's Ready. Raise. Rise.™ Recognizes 23 Cancer Advocacy Groups in Immuno-Oncology Research Awareness Campaign
Oct 9, 2015 03:02PM Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Expanded FDA Approval in Previously-Treated Metastatic Non-Small Cell Lung Cancer (NSCLC), Offering Improved Survival to More Patients
Oct 6, 2015 07:00AM U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs
Oct 5, 2015 05:26PM Market Wrap: Twitter Affirms Dorsey as CEO; DuPont CEO Kullman to Step Down; Peltz Gets Active on GE
Oct 1, 2015 06:59AM Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Sep 28, 2015 09:00AM Bristol-Myers Squibb Launches Working Together for Patients, a Program Highlighting the Company’s Commitment to Patients
Sep 28, 2015 03:30AM REPEAT/Actor Jack Huston Challenges Europeans to Take ACTion Against Lung Cancer
Sep 27, 2015 06:01PM Opdivo (nivolumab) Demonstrates Long Term Survival Benefit in Patients with Previously Treated Non-Squamous Non-Small Cell Lung Cancer in CheckMate -057
Sep 26, 2015 05:24AM Actor Jack Huston Challenges Europeans to Take ACTion Against Lung Cancer
Sep 25, 2015 06:01PM Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma
Sep 25, 2015 04:15PM Bristol-Myers Squibb Announces U.S. Food and Drug Administration Regulatory Filing Update for the Opdivo+Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma
Sep 25, 2015 08:00AM Bristol-Myers Squibb and Moffitt Cancer Center Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Program
Sep 24, 2015 03:17PM CORRECTING and REPLACING Bristol-Myers Squibb to Announce Results for Third Quarter 2015 on October 27
Sep 24, 2015 03:17PM Bristol-Myers Squibb to Take Part in Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
Sep 22, 2015 09:00AM Bristol-Myers Squibb to Announce Results for Third Quarter 2015 on October 27
Sep 21, 2015 08:00AM Bristol-Myers Squibb Selects ZS to Support Global Commercial Analytics
Sep 18, 2015 08:00AM Bristol-Myers Squibb Foundation Awards Additional Grants to Promote Cervical Cancer Screenings and Services for Women Living with HIV in Tanzania
Sep 17, 2015 04:32PM Bristol-Myers Squibb Announces Dividend
Sep 16, 2015 08:00AM Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Renal Cell Carcinoma
Sep 10, 2015 10:00AM Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference
Sep 10, 2015 08:00AM Bristol-Myers Squibb Employees Cycle Nearly 2,900 Miles Across the Country to Raise Money for Cancer Research
Sep 10, 2015 07:00AM Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission
Sep 9, 2015 08:00AM Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent Acute Coronary Syndrom
Sep 7, 2015 12:45PM Follow-up Data from Two Pivotal Opdivo (nivolumab) Trials Demonstrates Sustained Survival Results in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Sep 7, 2015 12:45PM New Cohorts from CheckMate -012 Assess Optimal Dosing of Opdivo+Yervoy in the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Sep 2, 2015 04:15PM Bristol-Myers Squibb to Present New Data from its Immuno-Oncology Clinical Development Programs at 16th World Conference on Lung Cancer
Sep 2, 2015 04:15PM Bristol-Myers Squibb to Host Investor Teleconference to Discuss World Conference on Lung Cancer (WCLC) Highlights
Sep 2, 2015 08:00AM U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients
View More Recent Stories View Older Stories